HSHaifa Shen

Haifa Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haifa Shen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Mauro Ferrari

    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA

    8 shared publications
  • Xiaoyong Deng

    Institute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, PR China

    5 shared publications
  • Xuewu Liu

    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas 77030, USA

    5 shared publications
  • Donald R. Erm

    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas, USA

    4 shared publications
  • Guodong Zhang

    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas, USA

    4 shared publications
  • Qingpo Li

    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas, USA

    4 shared publications

Latest Publications

  • Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer

    by Ayesha Khalid, Joy Wolfram, Ilaria Ferrari, Chaofeng Mu, Junhua Mai, Zhizhou Yang, Yuliang Zhao, Mauro Ferrari, Xiaojing Ma, Haifa Shen

  • Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

    by Joy Wolfram, Krishna Suri, Yi Huang, Roberto Molinaro, Carlotta Borsoi, Bronwyn Scott, Kathryn Boom, Donatella Paolino, Massimo Fresta, Jianghua Wang, et al.

    Context: Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective: Formation of celastrol liposomes, to avoid the use of toxic solubilising agents. Materials and methods: Two different formulations of PEGylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalisation and anticancer activity was measured in prostate cancer cells. Results: Liposomal celastrol displayed efficient serum stability, cellular internalisation and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion: Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilising agents.


  • Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells

    by Mingzhen Zhang, Rong Xu, Xiaojun Xia, Yong Yang, Jianhua Gu, Guoting Qin, Xuewu Liu, Mauro Ferrari, Haifa Shen


  • Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay

    by Jia Fan, Yi Huang, Inez Finoulst, Hung-Jen Wu, Zaian Deng, Rong Xu, Xiaojun Xia, Mauro Ferrari, Haifa Shen, Ye Hu


  • Mesoporous Silica Coating on Carbon Nanotubes: Layer-by-Layer Method

    by Xiaoyong Deng, Ping Qin, Man Luo, Erlei Shao, Hui Zhao, Xing Yang, Yanwen Wang, Haifa Shen, Zheng Jiao, Minghong Wu


  • Open Access

    Delivery of gene silencing agents for breast cancer therapy

    by Haifa Shen, Vivek Mittal, Mauro Ferrari, Jenny Chang

    The discovery of RNA interference has opened the door for the development of a newclass of cancer therapeutics. Small inhibitory RNA oligos are being designed tospecifically suppress expression of proteins that are traditionally considerednondruggable, and microRNAs are being evaluated to exert broad control of geneexpression for inhibition of tumor growth. Since most naked molecules are notoptimized for in vivo applications, the gene silencing agents need to bepackaged into delivery vehicles in order to reach the target tissues as theirdestinations. Thus, the selection of the right delivery vehicles serves as a crucialstep in the development of cancer therapeutics. The current review summarizes thestatus of gene silencing agents in breast cancer and recent development of candidatecancer drugs in clinical trials. Nanotechnology-based delivery vectors for theformulation and packaging of gene silencing agents are also described.


  • Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery

    by Haifa Shen, Cristian Rodriguez-Aguayo, Rong Xu, Vianey Gonzalez-Villasana, Junhua Mai, Yi Huang, Guodong Zhang, Xiaojing Guo, Litao Bai, Guoting Qin, et al.

    Purpose: RNA interference has the potential to specifically knockdown the expression of target genes and thereby transform cancer therapy. However, lack of effective delivery of siRNA has dramatically limited its in vivo applications. We have developed a multistage vector (MSV) system, composed of discoidal porous silicon particles loaded with nanotherapeutics, that directs effective delivery and sustained release of siRNA in tumor tissues. In this study, we evaluated therapeutic efficacy of MSV-loaded EphA2 siRNA (MSV/EphA2) with murine orthotopic models of metastatic ovarian cancers as a first step toward development of a new class of nanotherapeutics for the treatment of ovarian cancer. Experimental Design: Tumor accumulation of MSV/EphA2 and sustained release of siRNA from MSV were analyzed after intravenous administration of MSV/siRNA. Nude mice with metastatic SKOV3ip2 tumors were treated with MSV/EphA2 and paclitaxel, and therapeutic efficacy was assessed. Mice with chemotherapy-resistant HeyA8 ovarian tumors were treated with a combination of MSV/EphA2 and docetaxel, and enhanced therapeutic efficacy was evaluated. Results: Treatment of SKOV3ip2 tumor mice with MSV/EphA2 biweekly for 6 weeks resulted in dose-dependent (5, 10, and 15 μg/mice) reduction of tumor weight (36%, 64%, and 83%) and number of tumor nodules compared with the control groups. In addition, tumor growth was completely inhibited when mice were treated with MSV/EphA2 in combination with paclitaxel. Furthermore, combination treatment with MSV/EphA2 and docetaxel inhibited growth of HeyA8-MDR tumors, which were otherwise resistant to docetaxel treatment. Conclusion: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer. Clin Cancer Res; 19(7); 1806–15. ©2013 AACR.


  • Multistage Vectored siRNA Targeting Ataxia‐Telangiectasia Mutated for Breast Cancer Therapy

    by Rong Xu, Yi Huang, Junhua Mai, Guodong Zhang, Xiaojing Guo, Xiaojun Xia, Eugene J. Koay, Guoting Qin, Donald R. Erm, Qingpo Li, et al.

    The ataxia‐telangiectasia mutated (ATM) protein plays a central role in DNA damage response and cell cycle checkpoints, and may be a promising target for cancer therapy if normal tissue toxicity could be avoided. The strategy presented here to target ATM for breast cancer therapy involves the use of liposomal‐encapsulated, gene‐specific ATM siRNA delivered with a well‐characterized porous silicon‐based multistage vector (MSV) delivery system (MSV/ATM). Biweekly treatment of MSV/ATM suppressed ATM expression in tumor tissues, and consequently inhibited growth of MDA‐MB‐231 orthotopic tumor in nude mice. At the therapeutic dosage, neither free liposomal ATM siRNA nor MSV/ATM triggered an acute immune response in BALB/c mice, including changes in serum cytokines, chemokines or colony‐stimulating factors. Weekly treatments of mice with free liposomal ATM siRNA or MSV/ATM for 4 weeks did not cause significant changes in body weight, hematology, blood biochemistry, or major organ histology. These results indicate that MSV/ATM is biocompatible and efficacious in inhibiting tumor growth, and that further preclinical evaluation is warranted for the development of MSV/ATM as a potential therapeutic agent.


  • Open Access

    Monitoring the progression of metastatic breast cancer on nanoporous silica chips

    by Jia Fan, Xiaoyong Deng, James W. Gallagher, Haiyu Huang, Yi Huang, Jianguo Wen, Mauro Ferrari, Haifa Shen, Ye Hu

    Breast cancer accounted for 15 per cent of total cancer deaths in female patients in 2010. Although significant progress has been made in treating early-stage breast cancer patients, there is still no effective therapy targeting late-stage metastatic breast cancers except for the conventional chemotherapy interventions. Until effective therapy for later-stage cancers emerges, the identification of biomarkers for the early detection of tumour metastasis continues to hold the key to successful management of breast cancer therapy. Our study concentrated on the low molecular weight (LMW) region of the serum protein and the information it contains for identifying biomarkers that could reflect the ongoing physiological state of all tissues. Owing to technical difficulties in harvesting LMW species, studying these proteins/peptides has been challenging until now. In our study, we have recently developed nanoporous chip-based technologies to separate small proteins/peptides from the large proteins in serum. We used nanoporous silica chips, with a highly periodic nanostructure and uniform pore size distribution, to isolate LMW proteins and peptides from the serum of nude mice with MDA-MB-231 human breast cancer lung metastasis. By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and biostatistical analysis, we were able to identify protein signatures unique to different stages of cancer development. The approach and results reported in this study possess a significant potential for the discovery of proteomic biomarkers that may significantly enhance personalized medicine targeted at metastatic breast cancer.


  • Nanovector delivery of siRNA for cancer therapy

    by H Shen, T Sun, M Ferrari

    RNA interference holds the promise to knock down expression of every cancer gene. Both academic laboratories and pharmaceutical companies have committed heavily on manpower and financial resources to develop small interfering RNA (siRNA) cancer therapeutics over the last decade. Although significant advances have been made in the design of siRNA therapeutics and mechanism of action on cancer cell killing, there are still many hurdles to overcome including effective delivery of therapeutics in vivo. Nanotechnology has had an important role in the development of delivery vectors so far. This article summarizes current nanovectors for siRNA delivery, discusses technical challenges in overcoming biological barriers, and introduces the multistage vector system for tumor-specific delivery.